List of Excipients in Branded Drug KALETRA

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AbbVie Inc	KALETRA	lopinavir and ritonavir	0074-0522	COPOVIDONE K25-31
AbbVie Inc	KALETRA	lopinavir and ritonavir	0074-0522	FERRIC OXIDE YELLOW
AbbVie Inc	KALETRA	lopinavir and ritonavir	0074-0522	POLYETHYLENE GLYCOL 3350
AbbVie Inc	KALETRA	lopinavir and ritonavir	0074-0522	POLYVINYL ALCOHOL

Kaletra Excipient Strategy and Commercial Opportunities

Last updated: October 25, 2026

Kaletra is the fixed-dose combination of lopinavir and ritonavir, marketed by AbbVie for HIV-1 infection. Its main pharmaceutical-development advantage is the tablet formulation, which uses excipient-enabled solubility and absorption enhancement to replace the high-burden oral solution. The commercial opportunity has shifted from originator exclusivity to generic manufacturing, pediatric reformulation, taste masking, low-alcohol delivery, and excipient supply.

What is Kaletra and how is it formulated?

Kaletra contains lopinavir and ritonavir in a 4:1 ratio by mass.

Product	Strength	Dosage form	Key commercial use
Kaletra	200 mg lopinavir/50 mg ritonavir	Film-coated tablet	Primary adult and pediatric solid dosage form
Kaletra	100 mg lopinavir/25 mg ritonavir	Film-coated tablet	Pediatric and dose-flexibility use
Kaletra	80 mg/20 mg per mL	Oral solution	Patients unable to swallow tablets, including selected pediatric patients

The tablets are the more important commercial product because they avoid the alcohol and propylene glycol burden of the oral solution and have better logistical characteristics. The oral solution remains relevant where swallowing, age, feeding-tube administration, or dose titration prevents tablet use. FDA product labeling identifies the solution’s inactive ingredients and its high alcohol and propylene glycol content as clinically relevant formulation characteristics (U.S. Food and Drug Administration [FDA], 2024a).

What active pharmaceutical ingredients does Kaletra contain?

Lopinavir is the primary antiviral protease inhibitor. Ritonavir is present at a lower dose mainly because it inhibits CYP3A-mediated metabolism and increases lopinavir exposure. This pharmacokinetic boosting strategy allows lopinavir to reach therapeutic concentrations at a lower dose.

The combination creates several formulation requirements:

• Poor aqueous solubility for the active ingredients.
• High sensitivity to gastrointestinal absorption conditions.
• Need for consistent lopinavir exposure despite food and physiological variability.
• Need to prevent dose segregation in a low-dose/high-dose combination.
• Need to control tablet dissolution while maintaining manufacturability.
• Need to accommodate ritonavir’s own physical and chemical properties.

What excipients are used in Kaletra tablets?

Kaletra tablets use a relatively compact excipient system centered on solubility enhancement, wetting, granulation, compression, flow, lubrication, and film coating.

Excipient or excipient class	Function in the tablet	Commercial relevance
Copovidone	Binder, polymeric carrier, solubility and dispersion aid	Important for solid dispersion and granulation performance
Sorbitan laurate	Surfactant and wetting agent	Supports dissolution of poorly soluble drug substance
Colloidal silicon dioxide	Glidant and moisture-flow aid	Improves powder flow and content uniformity
Sodium stearyl fumarate	Lubricant	Supports tableting with lower hydrophobicity than some conventional lubricants
Hypromellose	Film-coating polymer	Protects the tablet and controls appearance and handling
Polyethylene glycol or macrogol	Plasticizer and coating aid	Improves coating flexibility
Talc	Anti-tacking and coating aid	Supports coating process control
Titanium dioxide and iron oxide pigments	Opacifier and colorant	Supports product identification and light protection

The exact inactive-ingredient presentation can vary by label version and jurisdiction. U.S. labeling identifies copovidone, sorbitan laurate, colloidal silicon dioxide, and sodium stearyl fumarate in the tablet composition, with conventional film-coating materials used for the tablet exterior (FDA, 2024a; DailyMed, 2024).

Why is copovidone important in the Kaletra tablet?

Copovidone is commercially significant because it can function beyond a conventional binder. In a poorly soluble drug system, it can support amorphous dispersion, improve wetting, and limit recrystallization during processing and storage. Its molecular weight, residual moisture, peroxide level, and particle properties can affect dissolution and stability.

For a generic or reformulated Kaletra tablet, copovidone is therefore a critical material rather than a simple filler. Excipient suppliers can differentiate through:

• Low-peroxide grades.
• Controlled particle-size distribution.
• Consistent viscosity and molecular-weight profiles.
• Improved compaction behavior.
• Regulatory support for global submissions.
• Supply security for high-volume antiretroviral manufacturing.

What role does sorbitan laurate play?

Sorbitan laurate acts as a surfactant and wetting agent. It helps disperse hydrophobic lopinavir and ritonavir during dissolution. The excipient is a key technical element because a reduction in surfactant level or a change in mixing order can alter dissolution, content uniformity, and bioavailability.

A generic manufacturer cannot assume that substitution with a different surfactant will be clinically or regulatory neutral. A replacement may require comparative dissolution, stability, impurity, and bioequivalence work. The strongest commercial position for an excipient supplier is a qualified, pharmaceutically consistent grade supported by prior regulatory use.

What excipients are used in the Kaletra oral solution?

The oral solution has a materially different excipient strategy. It uses solvent, cosolvent, sweetening, flavoring, viscosity, and preservation functions to maintain high concentrations of lopinavir and ritonavir in a liquid product.

Oral-solution component	Primary function	Business implication
Ethanol	Solvent and cosolvent	Creates pediatric, labeling, shipping, and administration constraints
Propylene glycol	Cosolvent	Raises age-specific safety and dosing considerations
High-fructose corn syrup	Sweetener and vehicle component	Supports palatability but adds sugar burden
Glycerin	Cosolvent, humectant, viscosity modifier	Supports mouthfeel and solution stability
Povidone	Solubilization and viscosity support	Helps maintain drug distribution
Polysorbate 80	Surfactant	Supports solubilization of hydrophobic active ingredients
Acesulfame potassium and saccharin sodium	Sweeteners	Offset bitterness
Flavoring agents and menthol	Taste and sensory modification	Important for pediatric adherence
Sodium chloride	Tonicity and formulation adjustment	Supports product consistency

The U.S. label states that Kaletra oral solution contains approximately 42.4% alcohol and 15.3% propylene glycol by volume (FDA, 2024a). These concentrations create a significant barrier to pediatric and neonatal use. The label includes warnings involving premature infants, young children, and patients receiving medications that interact with alcohol or propylene glycol.

What commercial opportunities exist for Kaletra excipients?

1. Generic tablet excipients and formulation support

The largest near-term opportunity is supply to generic manufacturers. A supplier can sell:

• Copovidone for binding and solid-dispersion performance.
• Sorbitan laurate or alternative surfactants.
• Low-peroxide polymer grades.
• Direct-compression systems.
• Film-coating premixes.
• Process-development services.
• Analytical methods for dissolution and solid-state control.

The value is highest when the excipient supplier supports formulation transfer, scale-up, design-of-experiments work, and regulatory documentation rather than selling commodity material alone.

2. Low-alcohol pediatric liquid formulations

The oral solution has an obvious reformulation target: reducing or eliminating ethanol and propylene glycol while preserving solubility, stability, dose uniformity, and palatability.

Potential approaches include:

• Surfactant and polymeric micellar systems.
• Self-emulsifying or lipid-based delivery systems.
• Cyclodextrin complexation.
• Amorphous polymeric dispersions.
• pH-controlled aqueous systems.
• Suspensions with improved redispersibility.
• Powder-for-reconstitution products.
• Stick packs or unit-dose oral liquids.

A successful replacement would need to preserve the dose of both active ingredients and address bitterness, sedimentation, microbial control, and feeding-tube compatibility. Pediatric acceptability is a commercial requirement, not a secondary attribute.

3. Taste masking and adherence products

Lopinavir and ritonavir are bitter. The existing oral solution depends on multiple sweeteners and flavoring agents but remains difficult for some pediatric patients. Commercial opportunities include:

• Ion-exchange resin complexes.
• Lipid-coated drug particles.
• Microencapsulation.
• Multiparticulate sprinkle systems.
• Orally disintegrating mini-tablets.
• Flavored granules for soft food.
• Palatable powder-for-suspension products.

These technologies could support pediatric products with lower alcohol exposure and improved adherence. A multiparticulate product could also permit age-based dose adjustment without requiring a large liquid bottle.

4. Heat-stable and supply-chain optimized products

Kaletra is used in markets where cold-chain infrastructure is limited. Excipients that improve thermal stability, moisture resistance, and packaging compatibility can reduce distribution losses.

Relevant commercial inputs include:

• Moisture-scavenging packaging.
• Low-hygroscopic polymers.
• High-barrier blister systems.
• Stabilizing antioxidants where compatible.
• Excipient grades with controlled residual moisture.
• Film coatings that improve heat and humidity protection.

A stable solid dosage form has greater value in low- and middle-income markets than a technically sophisticated product that requires refrigerated or tightly controlled distribution.

5. Alternate fixed-dose combinations

Lopinavir/ritonavir has been used in fixed-dose combinations with other antiretroviral agents in certain markets. Excipients can support combination tablets by controlling:

• Drug-drug compatibility.
• Layered or multilayer tablet compression.
• Dissolution of multiple poorly soluble actives.
• Segregation between high- and low-dose components.
• Moisture sensitivity.
• Release profiles.

The opportunity depends on current treatment guidelines and procurement demand. The commercial position is stronger for products aligned with national HIV programs than for a reformulation that targets only a declining private market.

When does Kaletra lose exclusivity and what is the patent position?

Kaletra’s principal composition-of-matter and formulation exclusivity periods have expired in the United States. The key U.S. lopinavir/ritonavir patent family dates to the 1990s, and the principal patent term ended in the mid-2010s after applicable term adjustments and pediatric considerations. The commercial exclusivity case is therefore materially weaker than it was during the branded product’s peak.

Exclusivity category	Kaletra position
New chemical entity exclusivity	Expired
Primary composition patent protection	Expired
Core formulation patent protection	Expired or no longer a practical barrier in the U.S.
Pediatric exclusivity	Historical, not current
Orphan exclusivity	Not applicable
Data exclusivity	Expired
Biosimilar exclusivity	Not applicable because Kaletra is a small-molecule drug

The relevant regulatory question is no longer whether a new entrant can operate during the original Kaletra patent term. It is whether an entrant can obtain approval with a formulation that meets bioequivalence, stability, quality, and manufacturing requirements.

What is the Orange Book status of Kaletra?

Kaletra has been listed in the FDA’s Orange Book as an approved small-molecule drug product, not as a biologic. Historical Orange Book listings included patent and exclusivity information associated with the tablets and oral solution. Current commercial assessment requires reviewing the specific dosage form, strength, and listed patent status rather than treating “Kaletra” as a single regulatory entry (FDA, 2025).

An Orange Book listing does not itself establish a continuing market barrier. For a generic applicant, the relevant issues are:

• Whether any patent remains listed for the exact strength and dosage form.
• Whether paragraph IV certification is available.
• Whether the FDA has approved any ANDAs for the relevant product.
• Whether a 30-month stay or litigation injunction applies.
• Whether labeling carve-outs are needed for method-of-use claims.

Which companies are challenging or competing with Kaletra?

The competitive field includes:

1. Generic manufacturers of lopinavir/ritonavir tablets and oral solution.
2. Regional manufacturers supplying public-sector HIV programs.
3. Alternative ritonavir-boosted protease inhibitors.
4. Newer integrase-inhibitor regimens that have displaced older protease-inhibitor combinations.
5. Pediatric HIV suppliers developing more acceptable liquids and dispersible products.

The most important competitive threat is therapeutic substitution. Current HIV treatment guidelines generally favor integrase-inhibitor-based regimens, particularly dolutegravir-based combinations, over lopinavir/ritonavir in many treatment settings (World Health Organization, 2023). This reduces the addressable market for a premium Kaletra reformulation.

What paragraph IV, litigation, and settlement risks apply?

Kaletra’s principal paragraph IV risk was concentrated during the period when U.S. patents remained listed and commercially relevant. With core patent terms expired, new challenges are more likely to concern:

• Residual listed patents for specific formulations.
• Pediatric dosage forms.
• Manufacturing processes.
• Labeling claims.
• New delivery technologies owned by later entrants.
• Patent claims covering a redesigned excipient system.

A generic tablet using the same inactive-ingredient architecture may face less formulation-patent risk but still must establish bioequivalence and pharmaceutical equivalence. A reformulated liquid or multiparticulate product may create a new patent estate around composition, particle engineering, taste masking, or use in specific pediatric populations.

No current settlement should be assumed to provide meaningful market protection without product-specific review of the FDA Orange Book, district-court docket, and applicable agreement terms. Historical litigation is less important to present-day commercial planning than regulatory approval and therapeutic substitution.

How strong is the Kaletra patent estate?

The legacy Kaletra patent estate is weak for blocking generic entry because its principal terms have expired. A new formulation patent could still be valuable if it claims a technically narrow but commercially necessary feature, such as:

• A low-alcohol aqueous solution.
• A stable amorphous dispersion.
• A taste-masked pediatric multiparticulate.
• A specific excipient ratio that produces bioequivalent exposure.
• A heat-stable product suitable for non-cold-chain distribution.
• A feeding-tube-compatible formulation.

Patent strength would depend on claim breadth, enablement, prior art, bioequivalence data, and whether competitors can design around the claimed excipient combination.

What generic launch scenarios exist for Kaletra?

Scenario	Probability driver	Commercial result
Standard generic tablets	Established API and excipient supply	Price erosion and limited differentiation
Generic oral solution	Solubility, alcohol, and palatability hurdles	More limited competition than tablets
Low-alcohol pediatric liquid	Clinical and regulatory performance	Higher value but greater development cost
Dispersible or multiparticulate product	Pediatric acceptability and dose flexibility	Potential niche premium
New fixed-dose combination	Guideline and procurement adoption	Dependent on HIV-treatment policy
Branded reformulation	New patentable delivery system	Requires a clear clinical or adherence benefit

How does Kaletra compare with newer HIV products?

Kaletra has a formulation advantage over older liquid protease-inhibitor products because its tablet reduces solvent-related burdens. It has a commercial disadvantage against newer regimens because lopinavir/ritonavir generally requires more frequent dosing, has substantial drug-interaction liability, and has less favorable tolerability than many modern integrase-inhibitor combinations.

Factor	Kaletra	Newer integrase-inhibitor regimens
Formulation complexity	High for oral solution; moderate for tablet	Often moderate
Booster requirement	Yes, ritonavir included	Often no pharmacokinetic booster
Excipient opportunity	Strong in pediatric liquids and solubility systems	Strong in long-acting and pediatric platforms
Generic competition	Established or feasible	Varies by product and jurisdiction
Market growth	Constrained by treatment substitution	Generally stronger in first-line therapy
Patent opportunity	New delivery and pediatric formulations	Active product and delivery patents for newer products

What revenue exposure does Kaletra create for AbbVie and suppliers?

AbbVie’s current financial disclosures generally report HIV products within broader pharmaceutical categories rather than providing a consistently separate Kaletra revenue line. Kaletra therefore should not be valued as a standalone growth asset without product-level sales data.

Revenue exposure is more relevant in three areas:

• Residual branded sales in markets with limited access to newer regimens.
• Public-sector demand for pediatric and second-line HIV treatment.
• Excipient and contract-manufacturing sales to generic suppliers.

The strongest opportunity is not a premium adult tablet. It is a differentiated pediatric or low-resource-market product with lower alcohol burden, improved palatability, and robust stability.

Key Takeaways

• Kaletra’s core product is lopinavir/ritonavir in a 4:1 fixed-dose combination.
• Copovidone, sorbitan laurate, colloidal silicon dioxide, and sodium stearyl fumarate are central tablet excipients.
• The oral solution contains approximately 42.4% alcohol and 15.3% propylene glycol, creating a clear reformulation opportunity.
• Core Kaletra patent and exclusivity protection has expired in the United States.
• Current barriers are formulation performance, bioequivalence, pediatric safety, manufacturing scale, and market demand.
• The strongest excipient opportunities are low-peroxide copovidone, surfactant systems, pediatric taste masking, low-alcohol liquids, multiparticulates, and heat-stable products.
• Therapeutic substitution by newer HIV regimens limits the value of undifferentiated Kaletra reformulation.
• A new product needs a practical clinical or supply-chain benefit to support premium pricing.

FAQs About Kaletra Excipients and Commercial Opportunities

What is the most commercially important Kaletra excipient?

Copovidone is among the most important tablet excipients because it supports binding, dispersion, and dissolution of poorly soluble lopinavir and ritonavir.

Why is Kaletra oral solution difficult to reformulate?

The solution depends on ethanol and propylene glycol to maintain drug solubility. Replacing them requires a new balance of surfactants, polymers, taste masking, viscosity, stability, and microbial control.

Can a generic manufacturer change Kaletra’s excipients?

Yes. A generic manufacturer may use different inactive ingredients if the product meets applicable pharmaceutical-equivalence, bioequivalence, quality, stability, and labeling requirements.

Does Kaletra have biosimilar competition?

No. Kaletra is a small-molecule drug, so competition occurs through generic drug pathways rather than biosimilar applications.

Is a new Kaletra pediatric formulation patentable?

Potentially. A low-alcohol, taste-masked, dispersible, or heat-stable formulation may support patent claims if it is novel, non-obvious, enabled, and commercially distinguishable from prior art.

References

1. DailyMed. (2024). Kaletra: Lopinavir and ritonavir tablet, film coated; lopinavir and ritonavir solution. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (2024a). Kaletra prescribing information. FDA.

3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. World Health Organization. (2023). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: Recommendations for a public health approach. WHO.